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Abstract
MicroRNA (miRNA)-related single nucleotide polymorphisms (miR-SNPs) can affect cancer development, treatment efficacy
and patients prognosis. We examined 6 miR-SNPs in miRNA processing machinery genes including exportin 5 (XPO5)
(rs11077), Ran-GTPase (RAN) (rs14035), Dicer (rs3742330), Trinucleotide Repeat Containing 6B (TNRC6B) (rs9623117), GEMIN3
(rs197412), GEMIN4 (rs2740348) in 108 surgically resected HCC patients and evaluated the impact of these miR-SNPs on HCC
outcome. Among the 6 SNPs, only the A/A genotype of rs11077 located in XPO5 39UTR was identified to associated
independently with worse survival in HCC patients by multivariate analysis with relative risk, 0.395; 95% CI, 0.167–0.933;
p=0.034. This is the first study reporting that polymorphisms related to miRSNPs have prognostic value in hepatocellular
carcinoma and identify the A/A genotype of rs11077 SNP site located in XPO5 39UTR can help to predict worse prognosis in
patients.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer and is responsible for more than half a million deaths each
year, which makes it the third leading cause of cancer deaths
worldwide [1]. The severity of HCC and the lack of effective
treatment strategies make the disease a major challenge. This
disease is strongly associated with several risk factors, including
chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus
(HCV) infection, and alcohol abuse [2]. The incidence of HCC
has increased steeply in Asia and Africa, where HBV and HCV
infections are more prevalent than in other continents. HBV
infection is a challenging health issue in China, where approxi-
mately 93 million people are HBV carriers and 30 million have
chronic hepatitis B [2,3]. Alcohol abuse is also increasing in China,
where ,6.6% of males and 0.1% of females in the population
have been diagnosed with alcoholism [4]. Many of these people
develop liver disease, such as alcoholic hepatitis and cirrhosis,
which make them susceptible to HCC. Despite improved clinical
detection methods and therapies, the prognosis of post-operative
HCC patients is still poor, due to a high recurrence rate. While the
molecular mechanism of HCC carcinogenesis is still not fully
understood, there are many prognostic factors and predictors of
recurrence associated with the disease, including tumour size,
tumour quantity, cell differentiation, venous invasion and degree
of inflammation [5–9].
MicroRNAs (miRNAs) are RNA molecules with lengths of ,22
nucleotides that act as posttranscriptional regulators of mRNA
expression [10,11]. Over 1000 miRNAs have been identified in
humans, and these miRNAs are responsible for regulating the
expression of at least 30% of protein-coding genes. A growing
body of evidence suggests that miRNAs play important roles in a
broad range of biological processes, such as embryonic develop-
ment, cellular differentiation, proliferation, apoptosis, cancer
development and insulin secretion [10,11]. In the miRNA
processing, long primary transcripts of miRNAs (pri-miRNAs)
are processed in nucleus by the RNase III Drosha, transported to
the cytoplasm by the nuclear transport factor exportin-5 (XPO5)
and Ran-GTPase (RAN). In the cytoplasm, RNase III Dicer and
transactivation-responsive RNA-binding protein (TRBP) mediate
pre-miRNAs processing to release a 21-bp dsRNA, the RNA-
induced silencing complex (RISC) including GEMIN3 and
GEMIN4 will select one strand as the mature miRNA and guide
mature miRNAs to their target mRNA sites [10,12–16]. MiRNA
related single nucleotide polymorphisms (miR-SNPs), defined as
single nucleotide polymorphisms (SNPs) in miRNA genes, miRNA
binding site and miRNA processing machinery, can modulate
miRNA and targeted genes expression so as to affect cancer
development, therapeutic efficacy and patient’s prognosis [16–19].
In the present study, we genotyped 6 miR-SNPs in miRNA
processing machinery genes including XPO5 (rs11077), RAN
(rs14035), Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3
(rs197412), GEMIN4 (rs2740348) in 108 surgically treated HCC
patients and evaluated the impact of these miR-SNPs on HCC
outcome. The post-operated HCC patients enrolled in this study
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e92791were followed up with regular visit by laboratory tests combined
with ultrasound, contrast-enhanced computed tomography (CT)
or contrast-enhanced magnetic resonance imaging (MRI). A miR-
SNP in the 39UTR region of XPO5 was found to be an
independent prognostic marker for HCC outcomes.
Materials and Methods
Tissue specimens and DNA extraction
Blood samples were collected at the Bethune International
Peace Hospital from 108 HCC patients who underwent tumour
resection in the Department of Hepatobiliary Surgery between
Table 1. All the primers and probes used for genotyping of miR-SNPs.
Gene rs NCBI Primer sequence Probe sequence
XPO5 rs11077 (A/C) F GAATCTGGTCACCTGATGGGA S1 GTACCTCCAAGGACCAGGGCTGGGA
R GTGCCTGAGTGGACCTTGAG S2 TTTGTACCTCCAAGGACCAGGGCTGGGC
S3 AGTCTTTAGTGCTAACATCCCCTTT
RAN rs14035 (C/T) F GCACTTGCTCAAAATCTGTGA S1 TTTTAGTAATCATGTTTTAATGTAGAACC
R TAACAGCAAGAATTCCCAACC S2 TTTTTTTAGTAATCATGTTTTAATGTAGAACT
S3 TCAAACAGGATGGAACATCAGTGGATTT
GEMIN4 rs2740348 (G/C) F TTGCCTCTGAGAAGAAGTGG S1 TTTTTTTTGGGAGTAACAGGGCCCTCTTCCGAC
R GACTCAGGGATGGCTCTGTC
S2 TTTTTTTTTTTGGGAGTAACAGGGCCCTCTTCCGAG
S3 AGCCAGACTTGGTGTTGAGGCTGCTTTTTTT
TNRC6B rs9623117 (C/T) F TTTCTGTCTCCTCCTATCCAT S1 TCTCCCTGTTACTCTTAAGTAGTGC
R CATTAGTTTAGCCAACAAGGT S2 TTTTCTCCCTGTTACTCTTAAGTAGTGT
S3 CTCCTTTCCCCATCCACCCCATCTC
GEMIN3 rs197412 (T/C) F TAGAGAAACCTGTGGAAATCA S1 TTTTATGGTTTTGTGAGAAATAAAGTTAC
R GAAGAGGTTCTTGAGCTGTAA S2 TTTTTTTATGGTTTTGTGAGAAATAAAGTTAT
S3 TGAACAGAGAGTCCCTGTGTTGGCATTT
Dicer1 rs3742330 (A/G) F AAAGGTATCAAGGTCTCAGTTTG S1 TTTTTTTTTTCAATCTTGTGTAAAGGGATTAGA
R CTGCAGAGGATCACTGGAATC S2 TTTTTTTTTTTTTCAATCTTGTGTAAAGGGATTAGG
S3 CACCCTAACAGAGCAAGATCCAATATTTTTT
F:represents forwrad primer for PCR.
R:represents reverse primer for PCR.
S1 and S2 represent probes match to different alelle of the SNP.
S3 represents probes downstream of the SNP.
doi:10.1371/journal.pone.0092791.t001
Table 2. Univariate analysis of clinical characteristics associated with post-operational survival with HCC by log-rank test.
Characteristics No.cases 3 years survival rate (%) p value
Gender Male 88 33.0 0.052
Female 20 15.0
Age(years) #55 56 34.6 0.086
.55 52 25.0
Child classification A 94 34.0 0.014
B1 4 0 . 0
Portal vein thrombosis No 92 32.6 0.003
Yes 16 12.5
Size of the tumor (diameter/cm) #5 44 47.7 0.004
.5 64 17.2
TNM classification I 54 44.4 0.000
II 43 16.3
III 11 9.1
Rs11077 AA 93 24.7 0.010
AC+CC 15 60.0
doi:10.1371/journal.pone.0092791.t002
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Hospital Review Board approval, and informed consent per-
formed in compliance with the Declaration of Helsinki. All
participants provided their written informed consent to participate
in this study. A total of 114 patients enrolled in this study were
reviewed every 3 months for 3 years. Six patients were lost during
follow-up: one HBV-HCC patient in the first year, one HCV-
HCC and two HBV-HCC patients in the second year and one
HCV-HCC and one HBV-HCC patients in the third year. The
remaining 108 patients, including 87 HBV-HCC patients, 12
HCV-HCC patients and 9 alcohol-related HCC patients, were
assessed. None of these patients received adjuvant chemotherapy
or radiation therapy following HCC resection. Blood was also
collected from 80 healthy controls. Genomic DNA was extracted
immediately with a Wizard Genomic DNA extraction kit
(Promega, Madison, WI). All procedures were supervised and
approved by the hospital’s Human Tissue Research Committee.
Genotyping of miR-SNPs
The miR-SNP of the miRNA processing genes including XPO5
(rs11077), RAN (rs14035), Dicer(rs3742330),
TNRC6B(rs9623117), GEMIN3(rs197412), GEMIN4(rs2740348)
were genotyped using the Polymerase Chain Reaction - Ligase
Detection Reaction (PCR-LDR) assay with the forward and
reverse primers to amplify the DNA fragments flanking miR-SNPs
using the sequence in the NCBI SNP database (http://www.ncbi.
nlm.nih.gov/snp/). Polymerase Chain Reaction (PCR) was
performed using a PCR Master Mix Kit according to the
manufacturer’s instructions (Promega, Madison, WI). The ligation
was performed using the different probes matched to the miR-
SNPs, and the ligated products were separated using the ABI
PRISM Genetic Analyzer 3730XL (Applied Biosystems, Foster
City, CA). Polymorphisms were confirmed based on the length
difference of ligated products. All the primers and probes were
listed in Table 1.
Statistical analysis
Statistical analyses were performed using the SPSS 18.0
software package (SPSS Company, Chicago, IL). Overall survival
(OS) was calculated from the time of operation to last follow-up or
death. Survival curves were calculated using the Kaplan-Meier
method, and comparisons between the curves were analyzed using
the log-rank test. Multivariate survival analysis was performed
using a Cox proportional hazards model. A p value of ,0.05 was
considered statistically significant.
Results
Correlation between clinical characteristics of HCC
patients and overall survival
The relationship between the overall survival during the 3-year
follow-up and patients’ clinical characteristics was analysed using
the Kaplan–Meier method and the log-rank test. No differences
were detected in overall survival time among HBV-HCC, HCV-
HCC and alcohol-related HCC patients; therefore, we assessed
them together in further analyses. Sex and age were not
statistically significant predictors of post-operative survival time;
however, tumor size, tumor stage, child classification, portal vein
thrombosis and rs11077 SNP site located in XPO5 39UTR were
correlated with survival time in these patients (Table 2).
Association of XPO5 polymorphisms with HCC outcome
We genotyped these 6 miR-SNP of miRNA processing
machinery genes including XPO5 (rs11077), RAN (rs14035),
Dicer (rs3742330), TNRC6B (rs9623117), GEMIN3 (rs197412),
GEMIN4 (rs2740348) in 108 HCC patients and 80 healthy
controls, no statistically significant association (p,0.05) between
patients and healthy controls was detected (data not shown). We
subsequently evaluated their association for post-operational
survival with Kplan-Meier methods. Among 6 SNPs, only
rs11077 SNP site of XPO5 genes had prognostic impact on
post-operational survival of HCC with log-rank test analysis, the
Figure 1. Genotype of rs11077 SNP site in XPO5 and its
association with HCC survival. rs11077 SNP site in XPO5 (C/C: SNPs,
A/C: heterozygous SNP, A/A:WT). Cum= cumulative.
Table 3. Multivariate analysis of prognostic factors associated with HCC survival.
Factors Relative risk 95%C.I. P value
Child classification 1.915 1.067–3.436 0.030
TNM classification 1.525 1.023–2.274 0.038
Rs11077 0.395 0.167–0.933 0.034
Portal vein thrombosis 1.724 0.880–3.375 0.112
Size of the tumor 1.371 0.815–2.306 0.235
doi:10.1371/journal.pone.0092791.t003
SNPS in miRNA Processing Genes
PLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e92791three-year survival rate of A/A, and A/C+C/C ge patients were
24.7% and 60% respectively. The patients with A/A genotype of
XPO5 rs11077 SNP site show a shorter overall survival compared
with that of A/C+C/C genotypes (p=0.010) as shown in Figure 1.
We then performed multivariate analysis with the Cox
proportional hazards model for HCC outcome associated clinical
characteristics and rs11077 SNP genotypes in these patients. As
shown in Table 3, the rs11077 SNP was identified as an
independent predictor of HCC outcome (relative risk, 0.395;
95% CI, 0.167–0.933; p=0.034). Tumor stage, Child classifica-
tion, but not portal vein thrombosis and size of tumor, were
identified as independent predictive factors for HCC outcome.
These data further demonstrated that the A/A genotype of
rs11077 located in XPO5 39UTR was associated with worse
survival in HCC patients.
Discussion
In the present study, we report for the first time that miR-SNPs
have predictive value on post-operational survival of HCC
patients. The miR-SNP in miRNA processing machinery genes
of XPO5 are involved in the prognosis of HCC outcome. XPO5 is
found in the nuclear membrane and mediates the transport of pre-
miRNA between the nucleic and cytoplasmic compartments so as
to adjust the whole miRNA expression level. Knock down XPO5
expression leads to reduced miRNA levels [20]. A mutated and
inactive XPO5 resulted in reduced miRNA processing and
decreased miRNA target inhibition, the restored XPO5 seemed
as a tumor suppressor to reverse the impaired export of pre-
miRNA in colon cancer [21]. The miR-SNP of rs11077 of XPO5
has been identified for its association with the cancer risk of
esophageal cancer as well as the outcome of non-small-cell lung
cancer and multiple myeloma [16–19,22]. Nevertheless, the
mechanism how this SNP modified the HCC survival remain
unclear, this SNP located in 39UTR of XPO5 might affect mRNA
stability and associated with alter expression of XPO5. The altered
XPO5 expression may affect the miRNAs as a whole, leading to
overall suppression of miRNA expression profiles thereby mediates
the HCC survival. The fact that rs11077 C/C genotype show
association with reduced Renilla expression in a Renilla luciferase
39UTR reporter system implies that this SNP could modify XPO5
expression so as to result in overall expression of miRNA in
multiple myeloma cells [18]. Even though our results were
concordant with the previous studies in non-small-cell lung cancer
and multiple myeloma that A/C or C/C genotype of rs11077
associated with better outcome. Given the differential cell of origin
for cancers and differential cell type specificity of miRNA
transcriptomes, it is reasonable to assume that the effects of
miR-SNP will be modulated in a cell type-specific manner. The
role of XPO5 in hepatocellular cancer and the noncoding RNA
including miRNA binding at this SNP site to mediate XPO5
expression need to be further investigated.
In summary, this is the first report investigating miRSNPs
involved in the miRNA network in liver cancer. A polymorphism
in the binding site for diverse miRNA clusters in XPO5 was
associated with a significantly OS in hepatocellular carcinoma
patients. MiRSNPs emerged as new promising markers for disease
progression in cancer. Although miR-SNP studies for miRNA
processing machinery genes are still preliminary, our results are
encouraging, as they indicate that miR-SNPs could be used as
cancer prognosis marker. However, the results from this study
require validation in another larger HCC cohort study and in
laboratory-based functional studies. MicroRNAs have been
emphasised as a key factor in patients’ susceptibility to therapeutic
response in many complex diseases, including cancer [23]. The
analysis of genetic polymorphisms in miRNA processing genes
may help to identify patient subgroups with poor prognoses and
may, accordingly, help to refine therapeutic decisions regarding
HCC patients.
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